GLP-1 drugs like Ozempic may achieve up to 47 percent breast cancer risk reduction, per a 2026 ASCO study of 111,000 women.
The findings, published in JCO Oncology Practice, add to a growing body of evidence that semaglutide may offer cancer prevention benefits beyond weight loss.
What the 2026 ASCO Study Found About GLP-1 Drugs and Breast Cancer
Women with excess weight taking GLP-1 drugs were about 30% less likely to develop breast cancer than women not taking such medications.
A separate analysis presented at the same ASCO 2026 meeting showed an even stronger 47% breast cancer risk reduction in some patient subgroups.
The primary study analyzed health records of more than 111,000 women from the Penn Medicine health system across Pennsylvania and New Jersey.
Per HealthDay reporting, lead researcher Dr. Elizabeth McDonald of the University of Pennsylvania led the analysis.
Drugs studied included semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound) as the primary GLP-1 medications.
GLP-1 Breast Cancer Risk Reduction: Is It Just Weight Loss?
A key question is whether the breast cancer risk reduction comes from GLP-1’s direct biological effects or simply from weight loss itself.
Excess body fat raises estrogen levels, which is a known driver of hormone receptor-positive breast cancer, the most common type in women.
The 2026 study found that breast cancer risk reduction from GLP-1 drugs was larger than what weight loss alone would typically explain.
Researchers hypothesize that GLP-1 receptors present in breast tissue may be directly activated by the drugs, creating an independent protective mechanism.
Per Medical Daily reporting, cancer researchers say the weight-loss-independent effect is the most scientifically exciting finding in the data.
What This Means for Women Considering Ozempic or Wegovy
The study was observational, meaning it found an association between GLP-1 use and lower cancer rates but does not confirm causation yet.
Clinical trials specifically designed to test GLP-1 drugs as cancer prevention tools are now being planned following this observational data.
Women already taking GLP-1 drugs for diabetes or weight loss can view the breast cancer risk reduction as a potential additional benefit.
Women considering GLP-1 drugs solely for cancer prevention should wait for clinical trial results before making that decision with their doctor.
See our piece on AI health advice risks for context on how technology is reshaping medical data analysis.
Other Cancers Where GLP-1 Drugs Show Protective Evidence
GLP-1 drugs have shown protective signals in colorectal cancer, kidney cancer, and endometrial cancer in prior observational studies.
A 2024 meta-analysis found GLP-1 users had a 44% lower risk of colorectal cancer compared to matched controls not using the drugs.
Researchers believe GLP-1 receptors are present in multiple cancer cell types, which may explain the broad protective signals across cancer categories.
The American Cancer Society has called for prospective clinical trials to evaluate GLP-1 drugs specifically as cancer prevention agents.
Machine learning tools are accelerating cancer signal discovery in large datasets, as explored in our AI health analysis piece.
Related Articles
Trust Post Desk
A journalist and editor at TrustPost.org covering world and national news, technology updates and human-interest stories. They check every fact, interview sources in person or online, and aim to deliver clear, accurate reporting. Their work ranges from breaking news to in-depth features and daily newsletters. Outside the newsroom, they follow emerging trends and engage with readers on social media.
